Form 4: Jazz Pharma CEO's Stock Vesting & Tax Withholding

Jazz Pharmaceuticals plc's President & CEO, Renee D Gala, reported the vesting of performance share awards and subsequent tax-related share withholding.

Summary

• Renee D Gala, President & CEO of Jazz Pharmaceuticals plc, acquired 12,741 ordinary shares on January 16, 2026, through the vesting of performance share awards.
• These performance share awards were originally granted on March 3, 2023, and their vesting requirements were satisfied on January 16, 2026.
• Concurrently, 5,371 ordinary shares were disposed of at a price of $171.16 per share to cover tax obligations related to the vesting.
• Following these transactions, Renee D Gala beneficially owns 115,230 ordinary shares of Jazz Pharmaceuticals plc.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects the successful achievement of performance targets by the CEO, leading to the vesting of equity awards. For the company, it's a neutral event as it's a routine compensation disclosure.

Positives

• The vesting of 12,741 performance share awards indicates that the performance-based requirements set for these awards were successfully met.

Negatives

• 5,371 shares were withheld to satisfy tax obligations, which is a standard practice for equity compensation.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically related to executive compensation. Such filings are common across publicly traded companies as executives receive and vest equity awards, reflecting standard corporate governance and compensation practices.

Stakeholder Impact

• Shareholders: This is a routine disclosure of executive compensation and does not indicate any material change in company operations or strategy. It provides transparency on insider ownership.

Key Dates

Recommendation

This is a routine insider transaction filing (Form 4) detailing the vesting of previously granted performance share awards and subsequent tax withholding. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It simply reflects a standard compensation event for an executive.

Keywords

Jazz Pharmaceuticals, JAZZ, Form 4, Insider Transaction, Stock Vesting, Executive Compensation, Renee D Gala, Performance Share Awards